An investigation for investors in NASDAQ:XBIT shares was announced over potential breaches of fiduciary duties by certain XBiotech directors.
Investors who purchased shares of XBiotech Inc (NASDAQ:XBIT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain XBiotech directors breached their fiduciary duties and caused damage to the company and its shareholders.
On April 20, 2017, XBiotech Inc h announced that the European Medicines Agency rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech’s candidate antibody for the treatment of colorectal cancer. XBiotech Inc said that the negative trend vote indicates that it is unlikely that the Committee for Medicinal Products for Human Use will vote in favor of the MAA at its formal decision vote scheduled for May. XBiotech Inc advised investors that the key outstanding issues relate to clinical relevance of the therapy in the indication and quality assurance. Shares of XBiotech Inc (NASDAQ:XBIT) declined on April 21, 2017 to $9.80 per share.
Those who purchased NASDAQ:XBIT shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments